Glide names Bryan Morton chair
This article was originally published in Scrip
Oxford, UK-based Glide Pharma, a pharmaceutical and device company focused on needle-free administration of solid dose formulations, has named Bryan G Morton non-executive chair of the board. He joins the firm from oncology company EUSA Pharma, where he was CEO. He succeeds Dr Charles Potter who will step down from the board and his role as Glide's chief business officer.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.